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Italy Both IL-2 and IL-4 are potent activators of JAK3. This
shared effect is mediated by the presence of the com-
mon g chain (gc) in both the IL-2 and IL-4 receptors
Summary (Takeshita et al., 1992; Kondo et al., 1993; Russell et
al., 1993). The gc subunit is also a component of the
Both IL-2 and IL-4 bind to receptors containing the receptors for IL-7, IL-9, and IL-15 (Noguchi et al., 1993a;
common g chain and JAK3. Although JAK3 is required Kondo et al., 1994; Kimura et al., 1995; Giri et al., 1994).
for proper lymphoid development, the precise roles of JAK3 was shown to associate with gc (Boussiotis et al.,
this kinase in IL-2 and IL-4 signaling in lymphocytes 1994; Russell et al., 1994; Miyazaki et al., 1994), and the
have not been defined. Here, we have studied IL-2 and importance of this specific interaction was underlined
IL-4 signaling in B cell lines lacking JAK3. Although by the finding that mutations of either gc (Noguchi et al.,
IL-2-induced phosphorylation of IL-2Rb, JAK1, and 1993b; Puck et al., 1993) or JAK3 result in phenotypically
STAT5 all required the presence of JAK3, IL-4-medi- similar forms of SCID, inherited as X-linked and autoso-
ated phosphorylation of JAK1, STAT6, and insulin re- mal-recessive traits, respectively. Infants with JAK3-
ceptor substrates 1 and 2 did not. However, IL-4- SCID and X-linked SCID (XSCID) present with severe T
induced effects were clearly improved following JAK3 cell lymphopenia, normal to elevated numbers of non-
expression. These data indicate that IL-4 signaling oc- functional B cells, hypoplastic lymphoid organs, and
curs in the absence of of JAK3, but is comparatively extreme susceptibility to opportunistic infections, lead-
inefficient. These findings may help in understanding ing to early death unless successfully treated by alloge-
the pathogenesis of the immunodeficiency thatoccurs neic bone marrow transplantation. Cells obtained from
with mutations of JAK3 and may suggest a mechanism patients lacking the functional expression of JAK3 (or
for the pleiotropic effects of IL-4. gc) might be expected to suffer from the absence of the
biological effects induced by all cytokines using gc-
Introduction containing receptors.
IL-2 is known to induce phosphorylation of receptor
Cytokines are critical regulators of both the develop- subunits, activation of downstream signaling elements
ment and function of the cells of the immune system such as Janus kinases (JAK1 and JAK3) and STATs
(reviewed by Paul and Seder, 1994). Cytokines, such (STAT3 and STAT5), and stimulation of cell proliferation
as interleukin-2 (IL-2) and IL-4, mediate their effects (Johnston et al., 1994, 1995a;Witthuhn et al., 1994; Lin et
al., 1995; Fujii et al., 1995).Previous studies conducted in
murine fibroblasts transfected with human IL-2 receptor8 These authors contributed equally to this work.
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components indicated the involvement of JAK3 in IL-2- (Macchi et al., 1995) by immunoblotting whole-cell ly-
sates. Using an antibody raised against JAK3 (Figuremediated STAT5 activation and cell proliferation (Miya-
zaki et al., 1994; Fujii et al., 1995). However, the role of 1A, upper panel), control cells showed high expression
of JAK3, while CM cells showed no detectable JAK3JAK3 in IL-2-mediated responses in human lymphocytes
has not been defined. protein. Furthermore, lysates from unstimulated, IL-2-
stimulated, or IL-4-stimulated cells were immuno-Like IL-2, IL-4 induces rapid phosphorylation of JAK1
and JAK3 (Johnston et al., 1994; Witthuhn et al., 1994), precipitated with JAK3 antiserum, resolved by SDS–
polyacrylamide gel electrophoresis (SDS–PAGE), andbut the downstream signaling cascade differs at the
level of STAT activation. IL-4 stimulation does not result immunoblotted with an antiphosphotyrosine mono-
clonal antibody (Figure 1B, upper panel). As expected,in phosphorylation of STAT5, but instead activates
STAT6 (IL-4 STAT) (Hou et al., 1994). Presumably, this JAK3 was inducibly phosphorylated upon IL-2 and IL-4
stimulation in normal cells, while no JAK3-containingis one explanation for the distinct biological effects of
IL-4 and IL-2. IL-4 increases expression of CD23 (FceRII; immunocomplexes were detectable in the JAK3-defi-
cient B cells.Conrad et al., 1987) and major histocompatibility com-
plex class II (Noelle et al., 1984) and is critical for immu- One of the earliestdetectable events that occurs upon
ligand binding to cytokine receptors is the phosphoryla-noglobulin (Ig) heavy-chain switching for IgE and IgG4
in human B cells (reviewed by Coffman et al., 1993). IL-4 tion of the receptor itself. Therefore, we first asked
whether JAK3 was necessary for IL-2Rb chain phos-has also been shown to induce rapid phosphorylation
of the signaling proteins insulin receptor substrate 1 phorylation (Figure 1C). Normal donor BCL (Figure 1C,
lanes 1 and 2) and JAK3-deficient cells (lanes 3 and 4)(IRS-1) and IRS-2 (Wang et al., 1992; Sun et al., 1995).
However, the requirement for JAK3 in the IL-4-mediated were left unstimulated or were stimulated with IL-2 for
15 min. Lysates were then immunoprecipitated with ancellular responses has not been investigated.
To define the role of JAK3 in IL-2 and IL-4 cytokine antibody specific for IL-2Rb. We did not detect IL-2-
induced IL-2Rb chain phosphorylation in CM cells whensignaling, we used the naturally occurring model offered
by JAK3-deficient SCID B lymphocytes. Moreover, to compared with a normal donor BCL. The filter was sub-
sequently stripped and immunoblotted with IL-2Rbcompare signaling events in the presence and absence
of JAK3, we reconstituted JAK3 protein expression and antiserum to verify that equivalent amounts were immu-
noprecipitated (data not shown). The lack of phosphory-function in these cells (Candotti et al., 1996). We found
that phosphorylation of JAK1 and IL-2 receptor b (IL- lation of the IL-2Rb chain upon IL-2 stimulation was also
confirmed in another cell line lacking JAK3 expression2Rb) chain in response to IL-2 required JAK3. Similarly,
IL-2-induced STAT5 activation also required the pres- (data not shown).
As discussed below, we found that IL-2-mediated ty-ence of JAK3. In contrast with the dependency of IL-2
signaling on JAK3, we found several aspects of IL-4 rosine phosphorylation of JAK1 was also dependent
upon JAK3 expression.signaling preserved in the absence of JAK3. In particu-
lar, phosphorylation of JAK1 and activation of STAT6 Phosphorylation of the IL-2Rb chain is thought to pro-
vide a docking site for Src homology domain (SH2)-were clearly detectable in JAK3-deficient cells. More-
over, phosphorylation of IRS-1 and IRS-2 and marginal containing STAT proteins (Friedmann et al., 1996). A
member of the STAT family of transcription factors,up-regulation of CD23 surface expression were also
conserved in the absence of JAK3 expression. Together, STAT5, was shown to be activated in response to IL-2
(Hou et al., 1995; Lin et al., 1995; Fujii et al., 1995; John-these data indicate that while IL-2 responses seem
heavily dependent on the activity of JAK3, IL-4 signaling ston et al., 1995a). Using lymphoid cell lines lacking
JAK3, we examined whether JAK3 was necessary forcan clearly occur in the absence of JAK3 expression.
This residual IL-4 signal, however, appears much less phosphorylation of STAT5 (Figure 1D, upper panel). Nor-
mal donor BCL (Figure 1D, lanes 1–3) and JAK3-deficientefficient if compared with that observed in the presence
of JAK3 and is markedly improved upon JAK3 gene cells (lanes 4–6) were left unstimulated or were stimu-
lated with IL-2 or IL-4 for 15 min, lysed, and immunopre-reconstitution. The JAK3-independent IL-4 signaling
pathway may constitute the basis of IL-4 function in cipitated with STAT5 antiserum. The immunoprecipi-
tates were probed with a monoclonal antibody againstthose cells where JAK3 levels are low or absent, such
phosphotyrosine. We observed STAT5 tyrosine phos-as resting lymphocytes and monocytes. Moreover, the
phorylation in response to IL-2 in the cells from normalexistence of JAK3-independent signaling pathways may
subject (Figure 1D, lane 2) and, as expected, not inalso help explain some aspects of the pleiotropic effects
response to IL-4 (lane 3). No STAT5 phosphorylationof cytokines such as IL-4. Finally, these findings shed
was observed in CM JAK3-deficient cells in responsesome light on the mechanism responsible for the func-
to either IL-2 or IL-4 (Figure 1D, lanes 5 and 6). Wetional impairment affecting B lymphocytes from JAK3-
obtained similar results from the analysis of BCLs ob-deficient (and XSCID) patients.
tained from several other JAK3-deficient patients (F. C.
et al., unpublished data). These results suggest that,
Results in B lymphocytes, JAK3 is required for IL-2-induced
receptor phosphorylation and activation of STAT5.
IL-2 Signaling in JAK3-Deficient B Cells
We first analyzed the levels of expression of JAK3 in an JAK3 Is Not Essential for IL-4 Signaling
Epstein–Barr virus (EBV)-transformed B cell line (BCL) IL-4 is known to be an important mediator of B cell
proliferation and activation. STAT6 is a protein of thefrom a normal subject and in the CM BCL lacking JAK3
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Figure 1. Absence of JAK3 Abrogates IL-2 Signaling
(A) Lysates of BCL obtained from normal control (lane 1) or JAK3-deficient CM (lane 2) cells were subjected to SDS–PAGE and then
electrotransferred to a nylon filter. The membrane was immunoblotted (IB) with JAK3 antiserum (a-JAK3, top) and then stripped and reblotted
with JAK1 antiserum (a-JAK1, bottom) to verify equal loading.
(B) Control (lanes 1–3) and CM cells (lanes 4–6) were stimulated with the indicated cytokine for 15 min at 378C, lysed, and immunoprecipitated
(IP) with a-JAK3. Complexes were resolved by SDS–PAGE and detected by immunoblotting (IB) with monoclonal antibody specific for
phosphotyrosine (a-PY, top). The membrane was stripped, and the presence of JAK3 in immunocomplexes was verified by blotting with
a-JAK3 (bottom).
(C) Control (lanes 1–2) and JAK3-deficient (lanes 3–4) cells were left unstimulated or stimulated with IL-2 for 15 min, lysed, and immunoprecipi-
tated (IP) with IL-2Rb-specific antibody (a-IL-2Rb). Complexes were then immunoblotted (IB) with phosphotyrosine-specific monoclonal
antibody (a-PY).
(D) Control (lanes 1–3) and JAK3-deficient (lanes 4–6) cells were stimulated with the indicated cytokine for 15 min, lysed, and immunoprecipitated
(IP) with STAT5A-specific antiserum (a-STAT5A). After transfer to a nylon membrane, complexes were immunoblotted (IB) with a-PY (top).
The membrane was stripped and reblotted with a-STAT5A (bottom).
STAT family known to be activated by IL-4 (Hou et al., below, we found that IL-4-mediated phosphorylation of
JAK1 can occur, although suboptimally, in the absence1994). Stimulation with IL-4 leads to phosphorylation of
JAK3, an event that has been suggested to be required of JAK3. We further investigated whether IL-4 could
induce the activationof STAT6 in theabsence of JAK3 byfor IL-4-induced activation of STAT6 (Fenghao et al.,
1995; Russell et al., 1995; Izuhara et al., 1996). As shown first assessing ligand-induced tyrosine phosphorylation
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Figure 2. IL-4-Induced Activation of STAT6 in JAK3-Deficient Cells
(A) Control (lanes 1–3) and JAK3-deficient CM cells (lanes 4–6) were left unstimulated or stimulated with IL-4 or IL-13, lysed, and immunoprecipi-
tated (IP) with STAT6 antiserum (a-STAT6). After transfer to a nylon membrane, immunocomplexes were immunoblotted (IB) with phosphotyro-
sine-specific monoclonal antibody (a-PY, top). To verify equal loading, the membrane was stripped and reprobed with a-STAT6 (bottom).
(B) Normal (lanes 1–5) and JAK3-deficient (lanes 6–10) cells were left unstimulated or stimulated with IL-4 for 15 min. Lysates were then
incubated with 32P-labeled GAS-like element from the CD23 promoter, incubated with anti-STAT6 (a-STAT6) or controlantibody where indicated,
and electrophoresed on a polyacrylamide gel.
(Figure 2A). As a control, the effect of IL-13 was also bound DNA in response to ligand, we performed an
electrophoretic mobility shift assay (EMSA). We used ananalyzed, as this cytokine has been shown to induce
STAT6 phosphorylation but it does not activate JAK3 oligonucleotide corresponding to an interferon-g (IFNg)
activation sequence (GAS) element of the low affinity(Keegan et al., 1995; Welham et al., 1995). Normal donor
BCL (Figure 2A, lanes 1–4) and JAK3-deficient CM cells IgE receptor (FceRII, CD23) promoter region, since IL-4
is known to up-regulate expression of CD23 on B lym-(lanes 5–8) were left unstimulated or were stimulated
with IL-2, IL-4, or IL-13. Lysates were then immunopre- phocytes (Conrad et al., 1987).
BCL from normal control (Figure 2B, lanes 1–5) andcipitated with STAT6 antiserum and resolved by SDS–
PAGE before immunoblotting with anti-phosphotyrosine. JAK3-deficient cells (lanes 6–10) were left unstimulated
or were stimulated with IL-4, and lysates were assessedAs expected, both normal control and JAK3-deficient
cells showed IL-13-induced STAT6 phosphorylation to for their ability to bind the CD23 promoter GAS element.
As shown in Figure 2B, gel-retarded DNA-binding com-comparable levels, consistent with previous data sug-
gesting that IL-13 signaling is JAK3 independent. Inter- plexes were formed upon IL-4 stimulation in both JAK3-
deficient cells and normal control BCL. However,estingly, we observed IL-4-induced phosphorylation of
STAT6 in both normal and JAK3-deficient cells, although stronger complexes were observed in lysates from nor-
mal, JAK3-expressing cells. To determine whether thethe intensity of the signal was clearly reduced in the
cells lacking JAK3. We screened cells from several protein–DNA complexes contained STAT6, we per-
formed supershift analysis using a STAT6 antiserum.other JAK3-SCID patients and consistently found IL-4-
induced phosphorylation of STAT6, but at a reduced IL-4-induced complexes in lysates from normal and
JAK3-deficient cells could be shifted with STAT6-spe-level (F. C. et al., unpublished data). Our data provide
evidence that STAT6 can be phosphorylated in response cific antiserum (Figure 2B, lanes 4 and 9), but not with
control sera (lanes 5 and 10). Together, these resultsto IL-4 in the absence of JAK3 and suggest the existence
of an alternative IL-4 signaling pathway. indicate that in the absence of JAK3, IL-4 can induce
STAT6 DNA binding.To confirm this result further, we next evaluated
STAT6 DNA binding in response to IL-4 in the JAK3- Two other important elements that have been identi-
fied in IL-4 signaling are the large cytosolic dockingdeficient cells. Following cytokine-induced tyrosine
phosphorylation, STAT proteins dimerize, translocate proteins, IRS-1 and IRS-2. These molecules contain
many tyrosines, which upon phosphorylation can pro-to the nucleus, and bind consensus sequences in the
promoter regions of activated genes. To ascertain vide binding sites for SH2-containing proteins. IL-4 in-
duces IRS phosphorylation in a variety of systems andthat the phosphorylated STAT6 in JAK3-deficient cells
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IL-2-induced phosphorylation of JAK1 or STAT5 oc-
curred in the absence of JAK3. In addition, no STAT5
DNA-binding activity was observed in response to IL-2
in JAK3-deficient cells using an EMSA with an oligonu-
cleotide corresponding toa GAS element in the b-casein
promoter. However, IL-2-induced STAT5 DNA binding
was restored to levels observed in normal BCLs in the
gene-corrected CM-JAK3 cells (data not shown). Taken
together, these findings strongly indicate an important
role for JAK3 in IL-2-mediated IL-2Rb chain phosphory-
lation, as well as in JAK1 and STAT5 activation.
We next assessed the effects of JAK3 reconstitution
on IL-4 signaling. Interestingly, we found that although
IL-4 induced detectable tyrosine phosphorylation of
JAK1 in the absence of JAK3 (Figure 4D, upper panel,
lane 7), this response was considerably reduced in com-
parison with that of normal control cells (Figure 4D,
upper panel, lane 3) and markedly enhanced by the
reconstitution of JAK3 expression (Figure 4D, upper
panel, lane 11). We then analyzed phosphorylation of
STAT6 in response to IL-4 (Figure 5A, upper panel). We
observed that, in the presence of JAK3, the level of
STAT6 phosphorylation increased to near normal levels
Figure 3. IRS Phosphorylation in Response to IL-4 in JAK3-Deficient in CM-JAK3 cells (lanes 7–9) as compared with untrans-
Cells duced CM cells (lanes 4–6). Similarly, the IL-4-mediated
Control (lanes 1–2) and JAK3-deficient (lanes 3–4) cells were left STAT6 DNA-binding activity (Figure 5B) in CM-JAK3
unstimulated or stimulated with IL-4 for 15 min, lysed, and immuno- cells was comparable with that observed in normal con-precipitated (IP) with antiserum against both IRS-1 and IRS-2
trol BCL (lanes 1–5). These data indicate that IL-4-(a-IRS). After transfer to a nylon membrane, complexes were immu-
induced JAK1 phosphorylation and STAT6 DNA bindingnoblotted (IB) with monoclonal antibody against phosphotyrosine
(a-PY). activity, although preserved in the absence of JAK3, can
be clearly up-regulated in the presence of JAK3 and
suggest the existence of two IL-4 signaling pathways,
cell types, including lymphoid cells (Wang et al., 1995). only one of which is JAK3 dependent. We did not detect
To assess whether JAK3 is required for IL-4-induced IL-4-induced tyrosine phosphorylation of the Janus ki-
IRS phosphorylation, lysates of normal control BCL and nases JAK2 and TYK2 in JAK3-deficient or normal con-
CM cells that were left unstimulated or treated with IL-4 trol BCL (data not shown).
were immunoprecipitated with antibodies to IRS-1 and
IRS-2 (Figure 3). Immunocomplexes were then probed Up-Regulation of CD23 Surface Expression
with antiphosphotyrosine antibody. Interestingly, we in Response to IL-4
could detect IRS phosphorylation in response to IL-4 To determine the effects of the absence and the pres-
both in normal (Figure 3, lane 2) and JAK3-deficient ence of JAK3 on IL-4-induced gene expression, we stud-
cells (lane 4) at comparable levels, suggesting that IRS ied IL-4-mediated up-regulation of the surface marker
phosphorylation can occur independently of JAK3. CD23 (FceRII). Since CD23 antigen is expressed at low
density on normal B cells and is up-regulated in IL-4-
Correction of JAK3 Expression and Restoration activated B cells (Conrad et al., 1987), it represents a
of Cytokine Responsiveness suitable functional readout of IL-4 effects. In BCLs from
in JAK3-SCID Lymphocytes normal donors, the CD23 antigen could be clearly up-
To assess more carefully the role of JAK3 in IL-2 and regulated above the basal levels upon IL-4 stimulation
IL-4 signaling, JAK3 was expressed in the JAK3-defi- (Figure 6). It should be noted that EBV immortalization
cient cells using retroviral-mediated gene transduction itself causes a large increase in CD23 surface expres-
(Candotti et al., 1996). As shown in Figures 4A and 4C, sion, and therefore the effect of IL-4 is not as dramatic
JAK3 expression was restored to normal levels in these as it is for primary cells. In the JAK3-deficient cells, IL-4
cells and we could demonstrate tyrosine phosphoryla- stimulation resulted in only marginal but reproducible
tion of the newly expressed JAK3 in response to IL-2 up-regulation of CD23 expression, while in the JAK3-
and IL-4. The reconstituted cells (CM-JAK3) were then reconstituted cells the IL-4-mediated CD23 induction
used to assess the contribution of JAK3 on IL-2 and was comparable with that observed in normal controls.
IL-4 responses. This effect was specific for IL-4, as an equivalent amount
We first examined the role of JAK3 in IL-2 signaling of IL-2 showed no effect on CD23 surface expression
in these cells. We observed restoration of IL-2Rb phos- (data not shown). These results are consistent with the
phorylation in response to IL-2 stimulation (Figure 4B), findings described earlier in this work and suggest that
as well as that of IL-2-mediated tyrosine phosphoryla- IL-4 signaling in the absence of JAK3 is able to induce
tion of JAK1 (Figure 4D, upper panel) and STAT5 (Figure cellular events characteristic of cell activation, but does
so much less efficiently than when JAK3 is expressed.4E, upper panel) in the JAK3 gene-corrected cells; no
Immunity
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Figure 4. Correction of IL-2 and IL-4 Signaling by Reconstitution of JAK3 Expression
(A) Lysates from control (lane 1) and JAK3-deficient CM cells untransduced (lane 2) or transduced with JAK3-cDNA (CM-JAK3, lane 3) were
subjected to SDS–PAGE and transferred to filter. The membrane was immunoblotted (IB) with JAK3 antiserum (a-JAK3, top) and then stripped
and reblotted with JAK1 antiserum (a-JAK1, bottom) to verify equal loading.
(B) Control (lanes 1–2) and JAK3-deficient cells before (lanes 3–4) and after gene correction (lanes 5–6) were left unstimulated or stimulated
with IL-2, lysed, and immunoprecipitated (IP) with IL-2Rb-specific antibody (a-IL-2Rb). Complexes were then immunoblotted (IB) with phospho-
tyrosine-specific monoclonal antibody (a-PY).
(C) Control (lanes 1–3), JAK3-deficient (lanes 4–6) and JAK3-reconstituted cells (lanes 7–9) were stimulated with the indicated cytokine for 15
min, lysed, and immunoprecipitated (IP) with a-JAK3. Complexes were resolved by SDS–PAGE and detected by immunoblotting (IB) with a
monoclonal antibody specific for phosphotyrosine (a-PY, top). The membrane was stripped, and equal loading was verified by blotting with
a-JAK3 (bottom).
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Figure 5. Effects of JAK3 Reconstitution on STAT6 Activation and DNA Binding
(A) Control (lanes 1–3), JAK3-deficient CM (lanes 4–6), and JAK3-reconstituted CM-JAK3 cells (lanes 7–9) were left unstimulated or stimulated
with IL-2 or IL-4, lysed, and immunoprecipitated (IP) with STAT6 antiserum (a-STAT6). After transfer to nylon membrane, immunocomplexes
were immunoblotted (IB) with phosphotyrosine-specific monoclonal antibody (a-PY, top). To verify equal loading, the membrane was stripped
and reprobed with a-STAT6 (bottom).
(B) Normal (lanes 1–5), JAK3-deficient (lanes 6–9), and gene-corrected CM-JAK3 cells (lanes 10–13) were left unstimulated or stimulated with
IL-4. Clarified lysates were incubated with the 32P-labeled GAS element of the CD23 promoter, incubated with a-STAT6 or control antibody
where indicated, and subjected to SDS–PAGE.
Discussion for IL-4 signaling in tissues that do not express JAK3
or in resting lymphoid cells where JAK3 expression is
greatly reduced. This may be the case for B lympho-IL-2 and IL-4 are important immunoregulatory cytokines
that share similarities in their signal transduction path- cytes, as the levels of JAK3 are highly regulated by
cellular activation (Tortolani et al., 1995).ways. They both bind receptors containing a ligand-
specific subunit and the common gc, activate JAK1 and IL-2 binding to its receptor is known to induce tyrosine
phosphorylation of IL-2Rb and gc subunits, as well asJAK3, lead to phosphorylation of IRS-1 and IRS-2, and
induce lymphocyte proliferation. However, their path- intracellular substrates, including JAK1 and JAK3, and
members of the STAT family. In a previous report, theways diverge at the level of STAT activation. IL-2 has
been shown to induce tyrosine phosphorylation and ac- C-terminal 68 amino acids of gc were shown to be nec-
essary for IL-2Rb chain phosphorylation following stim-tivation of STAT5 and STAT3, whereas IL-4 activates
STAT6 in addition to STAT3. Using lymphocyte cell lines ulation with IL-2 (Asao et al., 1993). As this is the same
region of gc with which JAK3 associates (Miyazaki etderived from patients with SCID due to a deficiency in
JAK3, we found that IL-2 signaling is heavily dependent al., 1994), we set out to determine whether JAK3 itself
is necessary for IL-2Rb phosphorylation. In comparingon the presence of JAK3. Specifically, we could detect
no IL-2-induced phosphorylation of IL-2Rb, JAK1, or IL-2-stimulated SCID lymphocytes with and without
JAK3, we observed that JAK3 is essential for phosphory-STAT5. In contrast, IL-4 signaling remains partially con-
served in the absence of JAK3. We found that in the lation of IL-2Rb chain. Furthermore, in these cells, JAK3
seems to be critical for the IL-2-mediated activation ofJAK3-deficient lymphocytes, IL-4 induced phosphoryla-
tion of IRS-1 and IRS-2 and, marginally, of JAK1. We JAK1, since we could not detect any change in the
tyrosine phosphorylation state of JAK1 in response toalso detected activation of STAT6 as well as slight up-
regulation of CD23 surface expression. These observa- IL-2 stimulation.
The C-terminal 147 amino acids of the IL-2Rb cyto-tions provide evidence of a JAK3-independent IL-4 sig-
naling pathway that may have important implications plasmic tail were previously shown to be necessary for
(D) Control (lanes 1–4) and JAK3-deficient cells untransduced (lanes 5–8) or transduced with the JAK3 cDNA (lanes 9–12) were left unstimulated
or stimulated with IL-2, IL-4, or IFNg, lysed, and immunoprecipitated (IP) with JAK1-specific antiserum (a-JAK1). After electrotransfer, immu-
noblotting was performed with a-PY (top). The filter was subsequently stripped and reprobed with a-JAK1 (bottom).
(E) Control (lanes 1–3), JAK3-deficient (lanes 4–6), and JAK3-reconstituted cells (lanes 7–9) were stimulated with IL-2 or IL-4 for 15 min, lysed,
and immunoprecipitated (IP) with STAT5A-specific antiserum (a-STAT5A). Immunocomplexes were immunoblotted (IB) with a-PY (top). The
membrane was stripped and reblotted with a-STAT5A (bottom).
Immunity
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Figure 6. Effect of JAK3 on IL-4-Induced Ex-
pression of CD23
Control, CM, or CM-JAK3 cells were unstimu-
lated or stimulated with 500 U/ml of IL-4 for
48 hr at 378C in serum-free RPMI 1640. Cells
were then washed in PBS and assessed for
CD23 surface expression by FACScan analy-
sis as described in Experimental Procedures.
(A) Closed histograms represent cell surface
CD23 expression in RPMI 1640 culture me-
dium, while open histograms indicate CD23
expression in the presence of IL-4.
(B) IL-4 induction of CD23 is presented as the
ratio between the DMFI value observed in the
absence of IL-4 and that obtained upon IL-4
stimulation. Results are shown as mean 6
SEM of four independent experiments.
IL-2-induced phosphorylation of STAT5 (Fujii et al., 1995; Previous reports have described the effects of muta-
tions of JAK3 and gc on IL-4 signaling. Russell et al.Friedmann et al., 1996). STAT family members all have
a conserved C-terminal SH2 domain, a potential phos- (1995) did not observe activation of STAT6 by IL-4 in a
BCL from one JAK3-SCID patient. Likewise, Izuhara etphotyrosine-binding region. The SH2 domain is believed
to be critical for the recruitment of STATs to activated al. (1996), using BCLs from XSCID patients, found that
IL-4 failed to induce tyrosine phosphorylation of JAK3receptor complexes. According to the current model,
the IL-2Rb chain would first need to be phosphorylated and activation of STAT6. However, Matthews et al.
(1995) showed that in peripheral B cells from XSCIDbefore it could provide a binding site for the recruitment
of STAT5. Since we found that the IL-2Rb chain does patients IL-4 mediated residual Bcell activation, prolifer-
ation, and IgE secretion. Finally, IL-4 was found to signalnot get phosphorylated in JAK3-SCID lymphocytes, one
would predict that STAT5 might not be recruited or and induce gene expression in nonlymphoid cells (Obiri
et al., 1995; Murata et al., 1996; Schnyder et al., 1996)phosphorylated upon IL-2 stimulation. In agreement
with this prediction, in the absence of JAK3 we found that do not express gc and have been presumed to lack
JAK3.no STAT5 phosphorylation or DNA binding in response
to IL-2. Because of the apparent contradictions in these data,
and because the absence of JAK3 involvement in theWe have previously shown (Candotti et al., 1996) that
the reduced proliferative responses to IL-2 in the JAK3- nonlymphoid IL-4 signal has not been unequivocally
proven, it was important to investigate further the roledeficient cells can be restored to normal upon in vitro
gene correction. Together these findings suggest that of JAK3 in IL-4 signaling using cells with genetic abroga-
tion of JAK3 expression.IL-2-mediated signaling is heavily dependent on the
presence of JAK3 and indicate an important role for the To this end, we studied the IL-4 responses in BCLs
from several JAK3-SCID patients. We could detect aJAK3–STAT5 pathway for IL-2-mediated proliferation re-
sponses in lymphocytes. slight phosphorylation of JAK1 in response to IL-4. We
also found that STAT6 activation was preserved in theIL-4 plays an important role in promoting human B
cell activation and proliferation, as well as inducing im- absence of JAK3, albeit to a lesser extent than in normal
or the JAK3 gene-corrected cells. This JAK3-indepen-munoglobulin heavy-chain switching. IL-4 is also known
to activate STAT6, but the mechanism and involvement dent IL-4 signaling seems to have functional conse-
quences, as we could detect some up-regulation ofof JAK3 (and gc) in this pathway have been unclear.
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CD23 surface expression in response to IL-4 in the signal in lymphocytes, which may be important in terms
of gene regulation. Whether this pathway uses the IL-JAK3-deficient cells. However, since EBV-transformed
cell lines were used in which CD23 was already markedly 13R subunit or not remains to be seen. It is interesting
that despite their similarities, IL-4 and IL-13 are not en-up-regulated, the functional effect of IL-4 in the absence
of JAK3 is difficult to ascertain. IL-4-induced up-regula- tirely redundant. For example, IL-4 knockout mice have
compromised class switching (Kuhn et al., 1991). Like-tion of CD23 was, however, clearly improved upon re-
constitution of JAK3 protein expression. Thus, using wise, patients with XSCID and JAK3-SCID have impaired
B cell differentiation, indicating that the gc–JAK3-inde-either STAT6 activation or CD23 up-regulation as a
marker, IL-4 signaling seems more efficient in the pres- pendent signaling pathway is not sufficient to rescue
these cells. However, elevated serum levels of IgE canence of JAK3.
We also found IL-4-induced phosphorylation of IRS-1 be detected in some XSCID and JAK3-SCID patients in
the absence of other immunoglobulin isotypes (L. D. N.,and IRS-2 to be intact in the JAK3-deficient cells. These
large cytosolic docking proteins have many phosphotyr- unpublished data), thus suggesting that the gc–JAK3-
independent pathway can induce at least some func-osine residues, which provide binding sites for SH2-
containing molecules. The IL-4 receptor can recruit PI tional responses in B cells in vivo. Whether the failure
of IL-13 tosubstitute for IL-4 effects relates to its inability3-kinase through tyrosine phosphorylation of IRS-1 or
IRS-2 (Wang et al., 1992; White and Kahn, 1994; Sun et to activate cells via the gc–JAK3 pathway will need to
be assessed in the future. Although questions about theal., 1995; Johnston et al., 1995b), and IRS-1 has also
been shown to be important for IL-4-mediated prolifera- exact mechanism and functional significance remain,
our findings clearly indicate that IL-4 is able to signal intion (Keegan et al., 1994). Since IRS-1 and IRS-2 are
critical elements of IL-4 signaling, the IL-4-induced tyro- cells in which JAK3 is absent.
sine phosphorylation of these molecules in the absence
of JAK3 provides further evidence for the existence of Experimental Procedures
a JAK3-independent IL-4 signaling pathway.
IL-4 signaling in the absence of JAK3 may be relevant
Cell Lines and Cytokines
not only in patients with JAK3-SCID, but also under The CM cell line was derived from a patient with JAK3-SCID homozy-
normal circumstances. For example, levels of JAK3 pro- gous for a mutation of JAK3 that results in a premature termination
tein expression are highly regulated in both B and T codon and an absence of JAK3 protein expression (Macchi et al.,
1995). A retroviral vector containing a copy of JAK3 cDNA waslymphocytes (Kawamura et al., 1994; Johnston et al.,
constructed and used to transduce BCL from JAK3-SCID patient1994; Tortolani et al., 1995; Musso et al., 1995). In resting
CM as previously described (Candotti et al., 1996). Cells were main-lymphocytes and monocytes, levels of JAK3 protein are
tained in RPMI 1640 (Life Technologies, Gaithersburg, MD) and cul-extremely low, but then dramatically up-regulated upon
tured at 378C in 5% CO2. All tissue culture media were supplemented
T cell activation with PMA (Kawamura et al., 1994; John- with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), 2 mM
ston et al., 1994) or B cell activation with staphylococcal L-glutamine (Life Technologies), and 50 mg/ml gentamycin (Bio-
Whittaker, Walkersville, MD). Cytokines were provided by Dr. C.protein A Cowan (SAC) or antibodies to CD40 (Tortolani
Reynolds (National Cancer Institute, Frederick, MD).et al., 1995), and in monocytes with various cytokines
and LPS (Musso et al., 1995). Therefore, this JAK3-inde-
pendent IL-4 signaling pathway may be important in Immunoblotting and Immunoprecipitation
Cells were lysed in buffer containing 300 mM NaCl, 50 mM Tris–HCl,leukocytes when levels of JAK3 are minimal.
2 mM EDTA, 0.5% Triton X-100, 2.5 mM p-nitrophenyl p9-guanidino-Several lines of evidence suggest that IL-4 and IL-13
benzoate, 10 mg/ml aprotinin, and 10 mg/ml leupeptin. Lysates (100bind to the same receptor chain(s) (reviewed by Callard
mg of protein) were centrifuged at 12,000 3 g, boiled, subjected
et al., 1996). Recently, a murine subunit, termed IL-13Ra, to 8% SDS–PAGE, and electrotransferred onto nylon membranes
and a human IL-13-binding protein called IL-13R have (Immobilon-P, Millipore, Bradford, MA). Membranes were probed
with a rabbit polyclonal antibody directed against the C-terminusbeen identified that may be shared by IL-4 and IL-13
of JAK3 (a-JAK3; Kawamura et al., 1994) or a mouse monoclonal(Obiri et al., 1995; Hilton et al., 1996; Caput et al., 1996).
antibody specific for JAK1 (a-JAK1; Transduction Laboratories, Lex-Our results could be explained if IL-4 could use the IL-
ington, KY) following previously reported procedures (Johnston et13R chain as a second receptor subunit in the absence
al., 1994). For immunoprecipitations, cells (5 3 107 to 10 3 107) were
of a competent gc–JAK3 pathway. Such a proposal first placed in RPMI 1640 without FBS for 4 hr and then stimulated
seems reasonable since IL-13 signaling was intact in with IL-2, IL-4, IL-13, or IFNg (1000 U/ml) for 15 min and lysed in
the JAK3-deficient cells. This is consistent with previous the lysis buffer defined above supplemented with 200 mM sodium
orthovanadate. After centrifugation, postnuclear supernatants weredata indicating that IL-13 does not lead to activation of
immunoprecipitated with appropriate antibody. Rabbit polyclonalJAK3. It will be important to determine whether the
antibody specific for STAT5 (a-STAT5) was described previouslyJAK3-independent IL-4 signal in B cells is indeed depen-
(Liu et al., 1995). Rabbit anti–mouse JAK1 (a-JAK1) and rabbit anti–
dent upon the IL-13R. The exact role played by JAK1 human STAT6 (a-STAT6)polyclonal antibodies were purchased from
in this “alternative” IL-4 pathway also awaits further in- Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse monoclonal
vestigation. antibody 561 specific for IL-2Rb chain was used as previously de-
scribed (Johnston et al., 1994). Immunoprecipitates were thenIn summary, our data indicate that IL-4-mediated
washed, boiled, and resolved using SDS–PAGE. Precipitated com-phosphorylation of JAK1 and IRS, activation of STAT6,
plexes were then immunoblotted with anti-phosphotyrosine mouseand up-regulation of CD23 surface expression occur
monoclonal antibody (a-PY [4G10]; Upstate Biotechnology Inc.,
in the absence of JAK3, but at reduced levels. These Lake Placid, NY) or reprobed with original immunoprecipitation anti-
findings point to a second, as yet unidentified IL-4 sig- body as described (Johnston et al., 1994). Detection was then per-
naling pathway that is independent of JAK3. Interest- formed by enhanced chemiluminescence (ECL, Amersham Life Sci-
ence, Arlington Heights, IL).ingly, this pathway appears to be a less efficient IL-4
Immunity
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EMSA Coffman, R.L., Lebman, D.A., and Rothman, P. (1993). Mechanism
and regulation of immunoglobulin isotype switching. Adv. Immunol.Cells were placed in serum-free RPMI 1640 for 4 hr and then stimu-
lated with human IL-2 or IL-4 (1000 U/ml) for 15 min at 378C and 54, 229–270.
washed with phosphate-buffered saline. Cell pellets were resus- Conrad, D.H., Waldschmidt, T.J., Lee, W.T., Rao, M., Keegan, A.D.,
pended in equal volume of lysis buffer (0.5% NP-40, 50 mM Tris–HCl Noelle, R.J., Lynch, R.G., and Kehry, M.R. (1987). Effect of B cell
[pH 8.0], 10% glycerol, 100 mM EDTA [pH 8.0], 50 mM NaF, 150 stimulatory factor-1 (interleukin 4) on Fce and Fcg receptor expres-
mM NaCl,100 mM Na3VO4, 1 mM DTT, 400 mM phenylmethylsulfonyl- sion on murine B lymphocytes and B cell lines. J. Immunol. 139,
fluoride, and 1 mg/ml leupeptin and aprotinin) and incubated on ice 2290–2296.
for 30 min. Lysates were clarified by centrifugation at 12,000 rpm
Fenghao, X., Saxon, A., Nguyen, A., Ke, Z., Diaz-Sanchez, D., andfor 15 min at 48C, and supernatants were resuspended to a final
Nel, A. (1995). Interleukin 4 activates a signal transducer and activa-protein concentration of 5 mg/ml and stored at 2708C until use. For
tor of transcription (Stat) protein which interacts with an interferon-gassays, 10 ml of cell lysate was incubated with 1 ng of 32P-labeled
activation site-like sequence upstream of the Ie exon in a human Boligonucleotide in reaction buffer (40 mM KCl, 1 mM MgCl2, 0.1 mM cell line: evidence for the involvement of Janus kinase 3 and interleu-
EDTA, 0.5 mM DTT, 20 mM HEPES [pH 7.9], 6% glycerol, 0.1 mg/
kin-4 Stat. J. Clin. Invest. 96, 907–914.
ml poly[dI–dC], 1 mg/ml BSA) for 15 min at room temperature. Re-
Friedmann, M.C., Migone, T.S., Russell, S.M., and Leonard, W.J.actants were loaded (without loading dye) onto a 4.5% polyacryl-
(1996). Different interleukin 2 receptor b chain tyrosines couple toamide, 0.223 TBE gel, which had been prerun at 200 V for 60 min,
at least two signaling pathways and synergistically mediate interleu-and electrophoresed at 300 V for 2 hr. Gels were dried and exposed
kin 2-induced proliferation. Proc. Natl. Acad. Sci. USA 93, 2077–directly to film. For these studies, we used oligonucleotides corre-
2082.sponding to a GAS-like element found in the CD23 promoter
(59-AAGACCATTTCTAAGAAATCTATC-39). Oligonucleotides were Fujii, H., Nakagawa, Y., Schindler, U., Kawahara, A., Mori, H., Bouil-
synthesized with a 59 ACTG overhang on each end and labeled using leux, F., Groner, B., Ihle, J.N., Minami, Y., Miyazaki, T., and Taniguchi,
Klenow DNA polymerase and [32P]dCTP by standard techniques. T. (1995). Activation of Stat5 by interleukin 2 requires a carboxyl-
terminal region of the interleukin 2 receptor b chain but is not essen-
tial for the proliferative signal transmission. Proc. Natl. Acad. Sci.Flow Cytometry
USA 92, 5482–5486.Cells (5 3 105) were washed in PBS and then resuspended in PBS
with 2% BSA and 0.1% NaN3. The cells were first incubated with Giri, J.G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K.,
human IgG (1%; Sigma) to prevent nonspecific antibody association Kumaki, S., Namen, A., Park, L.S., Cosman, D., and Anderson, D.
to the Fc receptor. Cells were then incubated at 48C for 30 min in (1994). Utilization of the b and g chains of the IL-2 receptor by the
the presence of 25 ng of EBVCS-5 (anti–human CD23, IgG1) or an novel cytokine IL-15. EMBO J. 13, 2822–2830.
isotype control antibody, both labeled with phycoerythrin (Becton
Hilton, D.J., Zhang, J.G., Metcalf, D., Alexander, W.S., Nicola, N.A.,
Dickinson, San Jose, CA). Quantitation of the surface staining of and Willson, T.A. (1996). Cloning and characterization of a binding
1 3 104 cells was performed using a FACScan flow cytometer, and subunit of the interleukin 13 receptor that is also a component of
data were computed using Cellquest software (Becton Dickinson). the interleukin 4 receptor. Proc. Natl. Acad. Sci. USA 93, 497–501.
The mean fluorescence intensity (MFI) indicates the channel number
Hou, J., Schindler, U., Henzel, W.J., Ho, T.C., Brasseur, M., andin a linear scale, which corresponds to the mean of the fluorescence
McKnight, S.L. (1994). An interleukin-4-induced transcription factor:intensities obtained for a particular antibody. DMFIs were calculated
IL-4 Stat. Science 265, 1701–1706.for each sample by subtracting MFI values of isotype control stain-
ings from those relative to the CD23-specific antibody. Hou, J., Schindler, U., Henzel, W.J., Wong, S.C., and McKnight,
S.L. (1995). Identification and purification of human Stat proteins
activated in response to interleukin-2. Immunity 2, 321–329.Acknowledgments
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